693 related articles for article (PubMed ID: 32307653)
1. CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement.
Ulrich H; Pillat MM
Stem Cell Rev Rep; 2020 Jun; 16(3):434-440. PubMed ID: 32307653
[TBL] [Abstract][Full Text] [Related]
2. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
Fantini J; Chahinian H; Yahi N
Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32405156
[TBL] [Abstract][Full Text] [Related]
3. Progress in Studies on Structural and Remedial Aspects of Newly Born Coronavirus, SARS-CoV-2.
Gupta SP
Curr Top Med Chem; 2020; 20(26):2362-2378. PubMed ID: 32962613
[TBL] [Abstract][Full Text] [Related]
4. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells.
Wang K; Chen W; Zhang Z; Deng Y; Lian JQ; Du P; Wei D; Zhang Y; Sun XX; Gong L; Yang X; He L; Zhang L; Yang Z; Geng JJ; Chen R; Zhang H; Wang B; Zhu YM; Nan G; Jiang JL; Li L; Wu J; Lin P; Huang W; Xie L; Zheng ZH; Zhang K; Miao JL; Cui HY; Huang M; Zhang J; Fu L; Yang XM; Zhao Z; Sun S; Gu H; Wang Z; Wang CF; Lu Y; Liu YY; Wang QY; Bian H; Zhu P; Chen ZN
Signal Transduct Target Ther; 2020 Dec; 5(1):283. PubMed ID: 33277466
[TBL] [Abstract][Full Text] [Related]
5. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
6. Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic.
Brufsky A
J Med Virol; 2020 Jul; 92(7):770-775. PubMed ID: 32293710
[TBL] [Abstract][Full Text] [Related]
7. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2.
Catanzaro M; Fagiani F; Racchi M; Corsini E; Govoni S; Lanni C
Signal Transduct Target Ther; 2020 May; 5(1):84. PubMed ID: 32467561
[TBL] [Abstract][Full Text] [Related]
8. Overview of lethal human coronaviruses.
Chen B; Tian EK; He B; Tian L; Han R; Wang S; Xiang Q; Zhang S; El Arnaout T; Cheng W
Signal Transduct Target Ther; 2020 Jun; 5(1):89. PubMed ID: 32533062
[TBL] [Abstract][Full Text] [Related]
9. Novel coronavirus SARS-CoV-2 (Covid-19) dynamics inside the human body.
Saha A; Saha B
Rev Med Virol; 2020 Sep; 30(5):e2140. PubMed ID: 32686248
[TBL] [Abstract][Full Text] [Related]
10. Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
Giovane RA; Rezai S; Cleland E; Henderson CE
Rev Med Virol; 2020 Sep; 30(5):e2136. PubMed ID: 32644275
[TBL] [Abstract][Full Text] [Related]
11. Scientific research progress of COVID-19/SARS-CoV-2 in the first five months.
Li H; Liu Z; Ge J
J Cell Mol Med; 2020 Jun; 24(12):6558-6570. PubMed ID: 32320516
[TBL] [Abstract][Full Text] [Related]
12. Neurological injuries in COVID-19 patients: direct viral invasion or a bystander injury after infection of epithelial/endothelial cells.
Azizi SA; Azizi SA
J Neurovirol; 2020 Oct; 26(5):631-641. PubMed ID: 32876900
[TBL] [Abstract][Full Text] [Related]
13. Tumor markers as an entry for SARS-CoV-2 infection?
Xia P; Dubrovska A
FEBS J; 2020 Sep; 287(17):3677-3680. PubMed ID: 32738184
[TBL] [Abstract][Full Text] [Related]
14. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin.
Theoharides TC
Biofactors; 2020 May; 46(3):306-308. PubMed ID: 32339387
[No Abstract] [Full Text] [Related]
15. Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution!
Nguyen AA; Habiballah SB; Platt CD; Geha RS; Chou JS; McDonald DR
Clin Immunol; 2020 Jul; 216():108459. PubMed ID: 32418917
[TBL] [Abstract][Full Text] [Related]
16. Mesenchymal Stem Cell Therapy for COVID-19: Present or Future.
Golchin A; Seyedjafari E; Ardeshirylajimi A
Stem Cell Rev Rep; 2020 Jun; 16(3):427-433. PubMed ID: 32281052
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective.
Hosoki K; Chakraborty A; Sur S
J Allergy Clin Immunol; 2020 Aug; 146(2):285-299. PubMed ID: 32624257
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
Fantini J; Chahinian H; Yahi N
Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32862840
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine "storm" and risk factor for damage of hematopoietic stem cells.
Ratajczak MZ; Kucia M
Leukemia; 2020 Jul; 34(7):1726-1729. PubMed ID: 32483300
[TBL] [Abstract][Full Text] [Related]
20. COVID-19: Immunology and treatment options.
Felsenstein S; Herbert JA; McNamara PS; Hedrich CM
Clin Immunol; 2020 Jun; 215():108448. PubMed ID: 32353634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]